Table 1 Characteristics of the 668 included patients
Characteristics | Interval ≤ 30 days (608 patients) | Interval > 30 days (60 patients) | P-value |
|---|---|---|---|
Age (years) | 44.5 ± 11.0 | 44.8 ± 11.2 | 0.808a |
Gender | 0.304b | ||
Male | 462 (76.0%) | 42 (70.0%) | |
Female | 146 (24.0%) | 18 (30.0%) | |
CCI score | 0.088c | ||
0 | 519 (85.4%) | 56 (93.3%) | |
1 | 87 (14.3%) | 4 (6.7%) | |
≥ 2 | 2 (0.3%) | 0 (0%) | |
T categorye | 0.034c | ||
T1 | 54 (8.9%) | 3 (5.0%) | |
T2 | 86 (14.1%) | 6 (10.0%) | |
T3 | 299 (49.2%) | 27 (45.0%) | |
T4 | 169 (27.8%) | 24 (40.0%) | |
N categorye | 0.211c | ||
N0 | 47 (7.7%) | 5 (8.3%) | |
N1 | 339 (55.8%) | 29 (48.3%) | |
N2 | 101 (16.6%) | 7 (11.7%) | |
N3 | 121 (19.9%) | 19 (31.7%) | |
Stagee | 0.105c | ||
II | 77 (12.7%) | 7 (11.7%) | |
III | 263 (43.3%) | 19 (31.7%) | |
IVa | 268 (44.1%) | 34 (56.7%) | |
EBV DNA (103 copies/ml) | 5.6 (0–3290) | 6.1 (0–3660) | 0.476c |
lnDNAf | 7.5 ± 4.0 | 7.8 ± 4.1 | 0.504a |
WHO pathology | 0.728d | ||
I | 6 (1.0%) | 0 (0%) | |
II | 28 (4.6%) | 4 (6.7%) | |
III | 574 (94.4%) | 56 (93.3%) | |
IC cycles | < 0.001c | ||
1 | 75 (12.3%) | 5 (8.3%) | |
2 | 315 (51.8%) | 21 (35.0%) | |
3 | 187 (30.8%) | 18 (30.0%) | |
≥ 4 | 31 (5.1%) | 16 (26.7%) | |
Concurrent chemotherapy | 0.028b | ||
Yes | 497 (81.7%) | 42 (70.0%) | |
No | 111 (18.3%) | 18 (30.0%) |